Zhejiang Medicine CoSHSE:600216 -0.83%81 Days Payable is 67.04 as of Mar. 2026, which is 13% below its 10-year median of 76.77. GuruFocus rates SHSE:600216 with a GF Score™ of 81/100 and a GF Value™ of ¥13.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Zhejiang Medicine Co ranks worse than 63.99% on this metric.
The historical rank and industry rank for Zhejiang Medicine Co's Days Payable or its related term are showing as below:
SHSE:600216'
s Days Payable Range Over the Past 10 Years
Min: 63.07 Med: 76.77 Max: 96.23
Current: 65.19
During the past 13 years, Zhejiang Medicine Co's highest Days Payable was 96.23. The lowest was 63.07. And the median was 76.77.
SHSE:600216's Days Payable is ranked worse than 63.99% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs SHSE:600216: 65.19
Zhejiang Medicine Co's Days Payable
declined
from Mar. 2025 (78.52) to Mar. 2026 (67.04).
It may suggest that Zhejiang Medicine Coaccelerated paying its suppliers.
Zhejiang Medicine Co Days Payable Related Terms
Zhejiang Medicine Co Days Payable Historical Data
* Premium members only.
The historical data trend for Zhejiang Medicine Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Medicine Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhejiang Medicine Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zhejiang Medicine Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Medicine Co (SHSE:600216) has a Days Payable of 67.04 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Medicine Co and its competitors. This is 13% below median its historical median of 76.77. Over the past decade, Zhejiang Medicine Co's Days Payable has ranged from 63.07 to 96.23. According to the industry distribution chart, Zhejiang Medicine Co ranks #590 out of 922 companies in the Drug Manufacturers industry, placing it in the top 64%.
Is Zhejiang Medicine Co's Days Payable too high?
Zhejiang Medicine Co's current Days Payable of 67.04 is 13% below median its 10-year median of 76.77. Over the past 10 years, this metric has ranged from a low of 63.07 to a high of 96.23. The Drug Manufacturers industry median Days Payable is 90.61. Zhejiang Medicine Co's value of 67.04 is 26% below this industry median. Based on the distribution chart, Zhejiang Medicine Co ranks #590 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Medicine Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Medicine Co ranks #590 out of 922 companies for Days Payable. This places Zhejiang Medicine Co in the lower half of its industry. The industry median Days Payable is 90.61. Zhejiang Medicine Co's value of 67.04 is 26% below this benchmark. Historically, Zhejiang Medicine Co's own Days Payable has ranged from 63.07 to 96.23 over the past decade. While the company's 10-year median is 76.77 vs. the industry median of 90.61, Zhejiang Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Medicine Co's current Days Payable of 67.04 is 26% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Medicine Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Medicine Co's current Days Payable is 67.04, which is 13% below median its own 10-year median of 76.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.81, compared to a current price of ¥12.00 — trading 13.1% below its estimated fair value. The current Days Payable is 67.04, which is 13% below median its 10-year median of 76.77 and 26% below the Drug Manufacturers industry median of 90.61. Zhejiang Medicine Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current Days Payable is 67.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued.
The current stock price of ¥12.00 is trading 13.1% below its estimated GF Value™ of ¥13.81.
GuruFocus considers Zhejiang Medicine Co to be Modestly Undervalued.
Key valuation signals for SHSE:600216:
Days Payable: 67.04 (13% below median its 10-year median of 76.77)
GF Value™: ¥13.81 vs. price of ¥12.00 (13.1% below fair value)
Industry Position: 26% below the Drug Manufacturers median (#590 of 922)
No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
81GF Score
Get the complete analysis for SHSE:600216
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600216 has been successfully added to your 
